Goldman Sachs MarketBeta Russell 1000 Value Equity ETF (GVUS)
- Previous Close
43.69 - Open
43.42 - Bid 22.29 x 800
- Ask 66.85 x 800
- Day's Range
44.53 - 44.53 - 52 Week Range
43.42 - 46.15 - Volume
3 - Avg. Volume
18,971 - Net Assets 388.23M
- NAV 44.52
- PE Ratio (TTM) --
- Yield --
- YTD Daily Total Return 5.26%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.12%
The fund seeks to achieve its investment objective by investing at least 80% of its assets in equity securities included in its underlying index, in depositary receipts representing equity securities included in its underlying index, and in underlying stocks in lieu of depositary receipts included in its underlying index. The index is designed to measure the performance of the large- and mid-capitalization value segment of U.S. equity issuers, with a capping methodology.
Goldman Sachs
Fund Family
Large Value
Fund Category
388.23M
Net Assets
2023-11-28
Inception Date
Performance Overview: GVUS
Trailing returns as of 4/26/2024. Category is Large Value.
People Also Watch
Related ETF News
Research Reports: GVUS
Analyst Report: Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
RatingPrice TargetAnalyst Report: Dell Technologies Inc.
Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It is focused on premium personal computers and enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell is vertically integrated but has a robust ecosystem of component and assembly partners, and also relies heavily on channel partners to fulfill its sales.
RatingPrice TargetAnalyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetSTEL: Lowering target price to $28.00
STELLAR BANCORP INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target